This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere between 10% and 19.9%, depending on the drug, the Centers for Medicare & Medicaid Services announced today. 

The IRA requires drug companies to pay rebates to Medicare when prices for certain single-source and biosimilar prescription drugs covered under Part B increase faster than the rate of inflation. These 27 drugs are among the first rebatable drugs under the law. Part B drugs impacted by a coinsurance adjustment may change quarterly. For more information, see the CMS fact sheet.

Related News Articles

Blog
The editorial board of The Washington Post has published an opinion piece calling for payment cuts to hospitals and health systems as part of efforts to…
Blog
Earlier this month the Medicare Payment Advisory Commission (MedPAC) released its annual March report on the commission’s recommendations for Fiscal Year 2024…
Headline
The Centers for Medicare & Medicaid Services plans to extend the Medicare Advantage Value-Based Insurance Design Model for an additional five years,…
Blog
A recent Urban Institute report highlights the issue of medical debt but fails to examine two of the chief driving forces of this debt: inadequate enrollment…
Headline
A recent Urban Institute report highlighting medical debt fails to examine how inadequate health coverage drives this debt, writes Molly Smith, AHA’s group…
Headline
The Centers for Medicare & Medicaid Services this week released for comment initial guidance implementing a program for Medicare to negotiate prices…